A new publication from CorriXR Therapeutics, an oncology focused biotherapeutics company developing genetic medicines to overcome drug resistance in solid tumors, shows that its novel CRISPR-directed ...
Synnovation Therapeutics Inc. has described heterocyclic compounds acting as nuclear factor erythroid 2-related factor 2 (NFE2-related factor 2; NFE2L2; NRF2) inhibitors reported to be useful for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results